
Zoetis Inc.
ZTSNYSEHealthcareDrug Manufacturers - Specialty & Generic
Previous close
$77.74
+$2.72 · +3.63%
Pre-market
$78.44
+$0.70 · +0.90%
Aug 24, 6:36 AM ET
ZTS company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
96
Deep Value
Momentum
25
Weakening
Sentiment
66
Bullish
Risk resilience
57
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteZoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Kristin C. Peck
- Listed since
- Feb 1, 2013
- Employees
- 14,500
Market position
Day range
Current $77.74
52-week range
Current $77.74
- Open
- $75.29
- Previous close
- $75.02
- Volume
- 4.39M
- 0.63× average
- Average volume
- 6.99M
- Average daily volume
- Market cap
- 32.59B USD
- Beta
- 0.73
- Market reference 1
- 50-day average
- $76.0074
- +2.28% above average
- 200-day average
- $105.57
- -26.36% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 62.97B USD
- EV / EBITDA
- 15.48×
- Earnings yield
- 4.79%
- Free cash flow yield
- 4.09%
Profitability & efficiency
- Return on equity
- 80.25%
- Return on assets
- 17.28%
- Return on invested capital
- 21.54%
Financial health
- Current ratio
- 3.03×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 9.47B USD | 9.26B USD | 8.54B USD | 8.08B USD | 7.78B USD |
| Cost of goods sold | 2.79B USD | 2.86B USD | 2.71B USD | 2.6B USD | 2.46B USD |
| Gross profit | 6.67B USD | 6.4B USD | 5.83B USD | 5.48B USD | 5.31B USD |
| Research and development | 698M USD | 686M USD | 614M USD | 539M USD | 508M USD |
| Selling, general, and administrative | 2.38B USD | 2.32B USD | 2.15B USD | 2.01B USD | 2B USD |
| Operating expenses | 3.08B USD | 3B USD | 2.77B USD | 2.55B USD | 2.51B USD |
| Interest income | 93M USD | 106M USD | 105M USD | 50M USD | 6M USD |
| Interest expense | 243M USD | 242M USD | 258M USD | 237M USD | 236M USD |
| Depreciation and amortization | 487M USD | 497M USD | 491M USD | 465M USD | 448M USD |
| Operating income | 3.6B USD | 3.39B USD | 3.07B USD | 2.93B USD | 2.8B USD |
| Net income | 2.67B USD | 2.49B USD | 2.34B USD | 2.11B USD | 2.04B USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 82%
- 9 beats, 2 misses, 0 met estimates
- Average EPS surprise
- +3.00%
- 11 comparable reports
- Latest EPS result
- 1.87
- Estimate 1.85 · Beat by 1.08%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$98.33
26.49% upsidePrice history unavailable
High $160Average $98.33Low $80.00Rating distribution
32 ratingsZTS news
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
$2.00
2025 complete year+100.0% since 2021
2026 partial: $1.59
$1.00
2,021
$1.30
2,022
$1.50
2,023
$1.728
2,024
$2.00
2,025
$1.59
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 20, 2026 | $0.53Quarterly | Jul 20, 2026 | Sep 1, 2026 |
Dividend | Apr 20, 2026 | $0.53Quarterly | Apr 20, 2026 | Jun 2, 2026 |
Dividend | Jan 20, 2026 | $0.53Quarterly | Jan 20, 2026 | Mar 3, 2026 |
Dividend | Oct 31, 2025 | $0.50Quarterly | Oct 31, 2025 | Dec 2, 2025 |
Dividend | Jul 18, 2025 | $0.50Quarterly | Jul 18, 2025 | Sep 3, 2025 |
Dividend | Apr 21, 2025 | $0.50Quarterly | Apr 21, 2025 | Jun 3, 2025 |
Ex-dividend Jul 20, 2026
$0.53
Quarterly
Record Jul 20, 2026 · Payment Sep 1, 2026
Ex-dividend Apr 20, 2026
$0.53
Quarterly
Record Apr 20, 2026 · Payment Jun 2, 2026
Ex-dividend Jan 20, 2026
$0.53
Quarterly
Record Jan 20, 2026 · Payment Mar 3, 2026
Ex-dividend Oct 31, 2025
$0.50
Quarterly
Record Oct 31, 2025 · Payment Dec 2, 2025
Ex-dividend Jul 18, 2025
$0.50
Quarterly
Record Jul 18, 2025 · Payment Sep 3, 2025
Ex-dividend Apr 21, 2025
$0.50
Quarterly
Record Apr 21, 2025 · Payment Jun 3, 2025
ZTS peers
ETFs holding ZTS
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI928.97M0.04%2.3T USD0.03%$378.24+0.44%
Vanguard S&P 500 ETFVOO850.56M0.05%1.7T USD0.03%$703.71+0.39%
Vanguard Morningstar Mid-Cap ETFVO631.13M0.28%224.7B USD0.03%$82.97+0.53%
iShares Core S&P 500 ETFIVV423.93M0.05%891.84B USD0.03%$769.31+0.39%
State Street SPDR S&P 500 ETFSPY391.15M0.05%817.87B USD0.09%$765.72+0.41%
Vanguard Morningstar Value ETFVTV277.99M0.11%256.5B USD0.03%$226.4+0.54%
State Street Health Care Select Sector SPDR ETFXLV226.24M0.51%44.76B USD0.08%$174.62+1.29%
Vanguard Morningstar Mid-Cap Growth ETFVOT222.98M0.66%33.5B USD0.05%$305.46+0.79%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 928.97M
- Weight
- 0.04%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard S&P 500 ETFVOO- Market value
- 850.56M
- Weight
- 0.05%
- AUM
- 1.7T USD
- Expense ratio
- 0.03%
- Price / 1D
- $703.71+0.39%
Vanguard Morningstar Mid-Cap ETFVO- Market value
- 631.13M
- Weight
- 0.28%
- AUM
- 224.7B USD
- Expense ratio
- 0.03%
- Price / 1D
- $82.97+0.53%
iShares Core S&P 500 ETFIVV- Market value
- 423.93M
- Weight
- 0.05%
- AUM
- 891.84B USD
- Expense ratio
- 0.03%
- Price / 1D
- $769.31+0.39%
State Street SPDR S&P 500 ETFSPY- Market value
- 391.15M
- Weight
- 0.05%
- AUM
- 817.87B USD
- Expense ratio
- 0.09%
- Price / 1D
- $765.72+0.41%
Vanguard Morningstar Value ETFVTV- Market value
- 277.99M
- Weight
- 0.11%
- AUM
- 256.5B USD
- Expense ratio
- 0.03%
- Price / 1D
- $226.4+0.54%
State Street Health Care Select Sector SPDR ETFXLV- Market value
- 226.24M
- Weight
- 0.51%
- AUM
- 44.76B USD
- Expense ratio
- 0.08%
- Price / 1D
- $174.62+1.29%
Vanguard Morningstar Mid-Cap Growth ETFVOT- Market value
- 222.98M
- Weight
- 0.66%
- AUM
- 33.5B USD
- Expense ratio
- 0.05%
- Price / 1D
- $305.46+0.79%
Continue in GoAI
Research ZTSresearch.disclaimer











